Login / Signup

Erythropoiesis and estimated fluid volume regulation following initiation of ipragliflozin treatment in patients with type 2 diabetes mellitus and chronic kidney disease: A post-hoc analysis of the PROCEED trial.

Tatsuya MaruhashiAtsushi TanakaKanae TakahashiYukihito HigashiKoichi Nodenull null
Published in: Diabetes, obesity & metabolism (2024)
PROCEED trial (registration number: jRCTs071190054).
Keyphrases
  • chronic kidney disease
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • end stage renal disease
  • randomized controlled trial
  • open label
  • combination therapy